___

• Folkman J, Shing Y. Angiogenesis. J Biol Chem 1992;267:10931–34
• Folkman J. Clinical applications of research on angiogenesis. N Eng J Med 1995;333:1757-63
• Perez-Atayde AR, Sallan SE, Tedrow U, et al. Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia. Am J Pathol 1997;150:815-21
• Ribatti D, Vacca RD, Nico B, et al. Angiogenesis spectrum in the stroma of B-cell non-Hodgkin’s lymphomas. An immunohistochemical and ultrastructural study. Eur J Haematol 1996;56:45-53
• Padro T, Ruiz S, Bieker R, et al. Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia. Blood 2000;95:2637-44
• Vacca A, Ribatti D, Presta M, et al. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood 1999;93:3064-73
• Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990; 82:4-6
• Fidler IJ, Ellis LM. The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell 1994;79:185- 8
• Parikh AA, Ellis LM. The vascular endothelial growth factor family and its receptors. Hematol Oncol Clin North Am 2004;18:951-71
• Ferrara N. VEGF: An update on biological and therapeutic aspects. Curr Opin Biotechnol 2000;11:517-24
• Klagsbrun M, D’Amore P. Vascular endothelial growth factor and its receptors. Cytokine Growth Factor Rev 1996;7: 259-70
• Fayette J, Soria JC, Armand JP. Use of angiogenesis inhibitors in tumour treatment. Eur J Cancer 2005; 41:1109- 16
• Aguayo A, Kantarjian H, Manshouri T et al. Angiogenesis in acute and chronic leukemias and myelodsyplastic syndromes. Blood 2000;96:2240-5
• Belgore FM, Lip GYH, Bareford D, et al. Plasma levels of vascular endothelial growth factor (VEGF) and its receptor, Flt-1, in haematological cancers: a comparison with breast cancer. Am J Haematol 2001;66:59-61
• Salven P, Teerenhovi L, Joensuu H. A high pretreatment serum vascular endothelial growth factor concentration is associated with poor outcome in non- hodgkin’s lymphoma. Blood 1997;90: 3167-72
• Fiedler W, Graeven U, Ergün S, et al. Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia. Blood 1997; 89:1870-5
• Di Raimondo F, Palumbo GA, Molica S, Giustolisi R. Angiogenesis in chronic myeloproliferative Haematol 2001;106:177-83 diseases. Acta
• Palmblad J. Angiogenesis in haematologic malignancies with focus on multiple myeloma. Haema 2001;4:89-98
• Dickson DJ, Shami PJ. Angiogenesis in acute and chronic leukemias. Leukemia and Lymphoma 2001;42:847-53 20. Podar K, Anderson KC.The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications. Blood 2005;105:1383-95
• Wierzbowska A, Robak T, Wrzesien-Kus A, et al. Circulating VEGF and its soluble receptors sVEGFR-1 and sVEGFR-2 in patients with acute leukemia. Eur Cytokine Netw 2003;14:149-53
• Aguayo A, Kantarjian HM, Estey EH, et al. Plasma vascular endothelial growth factor levels have prognostic significance in patients with acute myeloid leukemia but not in patients with myelodysplastic syndromes. Cancer 2002;95:1923-30
• Urba ska-Rys H, Wierzbowska A, Robak T. Circulating angiogenic cytokines in multiple myeloma and related disorders. Eur Cytokine Netw 2003;14:40-51
• Alexandrakis MG, Passam FH, Boula A et al. Relationship between circulating serum soluble interleukin-6 receptor and the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in multiple myeloma. Ann Hematol 2003;82:19-23